Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!
LT-02 is designed to treat ulcerative colitis by improving the barrier function of the colon through a delayed release formula.
The company intends to move forward with the Phase III trial of LT-02 in ulcerative colitis patients.
More Articles on Gastroenterology:
Olympus Surgical Video System Receives FDA 510(k) Clearance
8 Gastroenterology Devices Receive FDA 510(k) Clearance in March
American Cancer Society Awards Dr. Stephen Meltzer Research Grant
